February 22, 2024
amsterdam, netherlands – Argenx (Euronext & Nasdaq: ARGX), a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, today announced a conference call and audio on Thursday, February 29, 2024 at 2:30 p.m. announced that they would be hosting a webcast. At 8:30pm CET (Eastern Time), he will discuss full-year 2023 financial results and provide a fourth quarter business update.
A webcast of the live call can be accessed from the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on his website at argenx for approximately one year after the presentation.
About Argenx
argenx is a global immunology company dedicated to improving the lives of people living with severe autoimmune diseases. Through its Immunology Innovation Program (IIP), argenx partners with leading academic researchers to translate breakthrough advances in immunology into a world-class portfolio of novel antibody-based medicines. argenx develops and commercializes the first neonatal Fc receptor (FcRn) blocker approved in the United States, Japan, Israel, the European Union, United Kingdom, Canada, and China. The company is evaluating efgartigimod in multiple serious autoimmune diseases and is advancing several early-stage experimental drugs within its therapeutic franchise. For more information, please visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For more information, please contact us below.
media:
ben petok
BPetok@argenx.com
Investor:
Alexandra Roy (USA)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
